Experience with *Saccharomyces boulardii* Probiotic in Oncohaematological Patients

Beata Sulik-Tyszka¹ · Emilian Snarski² · Magda Niedźwiedzka² · Małgorzata Augustyniak² · Thorvald Nilsen Myhre² · Anna Kacprzyk² · Ewa Swoboda-Kopeć¹ · Marta Roszkowska³ · Jadwiga Dwilewicz-Trojaczek² · Wiesław Wiktor Jędrzejczak² · Marta Wróblewska¹,４

Published online: 25 September 2017 © The Author(s) 2017. This article is an open access publication

**Abstract** Very few reports have been published to date on the bloodstream infections caused by *Saccharomyces* spp. in oncohaematological patients, and there are no guidelines on the use of this probiotic microorganism in this population. We describe the use of probiotic preparation containing *Saccharomyces boulardii* in a large group of oncohaematological patients. We retrospectively analysed the data from 32,000 patient hospitalisations at the haematological centre during 2011–2013 (including 196 haematopoietic stem cell transplant recipients) in a tertiary care university-affiliated hospital. During the study period, 2270 doses of *Saccharomyces boulardii* probiotic were administered to the oncohaematological patients. In total, 2816 mycological cultures were performed, out of which 772 (27.4%) were positive, with 52 indicating digestive tract colonisation by *Saccharomyces* spp., mainly in patients with acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) or multiple myeloma (MM). While colonised, they were hospitalised for 1683 days and 416 microbiological cultures of their clinical samples were performed. In the studied group of patients, there were six blood cultures positive for fungi; however, they comprised *Candida* species: two *C. glabrata*, one *C. albicans*, one *C. krusei*, one *C. tropicalis* and one *C. parapsilosis*. There was no blood culture positive for *Saccharomyces* spp. Our study indicates that despite colonisation of many oncohaematological patients with *Saccharomyces* spp., there were no cases of fungal sepsis caused by this species.

**Keywords** *Saccharomyces boulardii* · Probiotic · Leukaemia · Lymphoma · Haematology

**Introduction**

*Saccharomyces boulardii* is a fungus classified as a yeast, which routinely cannot be distinguished from *Saccharomyces cerevisiae* and at present is regarded as a subtype of *S. cerevisiae* [1–6]. These yeasts are widespread in nature and can be found on plants, fruit and in soil, being also used in the baking and brewing industry [1, 2]. Usually, they are considered to be nonpathogenic commensals of the digestive tract, administered as probiotics for several indications, including *Clostridium difficile*-associated disease [4, 7–16].

However, since the 1990s, an increasing number of publications of fungemia and invasive infections caused by *Saccharomyces cerevisiae* (*boulardii*), particularly among intensive care unit (ICU) patients and individuals with multiple co-morbidities, have been reported in literature in patients treated with a probiotic preparation containing this yeast [1, 2, 5, 6, 11, 17–21]. Furthermore, it can also cause infections in otherwise healthy individuals [13, 17, 22–24].

Diarrhoea and colonisation of the gastrointestinal tract by potentially pathogenic bacteria including *Clostridium difficile* are important problems in care of oncohaematological patients treated for leukaemia and lymphoma [25]. One of the possible
approaches to this problem is to use probiotics containing *Saccharomyces boulardii* [26]. Both McFarland, and Videlock and Cremonini in their meta-analyses comprising 5029 patients and 4138 patients, respectively, concluded that probiotic preparations containing *Saccharomyces boulardii* reduced the incidence of antibiotic-associated diarrhoea (AAD) [8, 27].

However, there are concerns that probiotics might lead to severe invasive infections in some patients. This notion is supported by some case reports of *S. boulardii* or *S. cerevisiae* sepsis [1, 9, 18, 28]. This risk is emphasised in guidelines for infection prevention in haematological patients, in which probiotics usage is generally contraindicated or their possible use is not mentioned at all [29, 30]. Oral administration of probiotic preparation containing live yeasts may pose a particularly high risk to oncohaematological patients as they often suffer from severe immune deficiency due to malignancy [29]. Furthermore, immunosuppressive treatment itself predisposes these patients to infections and increases the risk of spread of microorganisms within the host. It should also be noted that oral mucositis and ulcers are very common in oncohaematological patients. It may lead to yeast translocation through the oral mucous membrane into the bloodstream, causing fungaemia and invasive infections linked to an increased mortality in this group of patients.

However, the basis of the above-mentioned guidelines relies on a limited number of published cases, and there is hardly any evidence from clinical trials to support this belief. The guidelines are based on two reports published in 1996. In one of them, 55 cases of *Lactobacillus* infections were reviewed—the mortality rate for the entire group was 6%; however, there were no deaths among the patients with acute myeloid leukaemia (AML) (*n* = 1), HIV (*n* = 3) and neutropenic fever (*n* = 3) [31]. In the other publication, a case was reported of a patient who developed *Mucor* spp. infection 5 months after haematopoietic stem cell transplantation (HSCT) and was using an excess of oral herbal remedies with *Saccharomyces boulardii* ([bioMerieux] tests and matrix-assisted laser desorption-ionisation time of flight mass spectrometry (MALDI-TOF MS) ([MALDI Microflex LT, Bruker, Germany]).

In this study, we report our experience with a wide use of a probiotic preparation containing *Saccharomyces boulardii* in patients with haematological neoplasms.

Patients and Methods

The study is a retrospective analysis of the hospital and medical data of the patients who were treated at the haematology and oncology ward from January 2011 until the end of December 2013 in a tertiary care university-affiliated teaching hospital (1050 beds).

The data from the microbiology department was used to assess the total number of microbiological cultures performed in the haematology and oncology department in the study period and find all of the patients who were colonised with fungi or had invasive fungal infections. Furthermore, we analysed the medical charts of all the patients who were colonised with *Saccharomyces boulardii* in order to assess their use of probiotics and antibiotics, the occurrence of colonisation and invasive infections caused by this yeast, as well as occurrence of neutropenia and previous treatment regimens used in this group of recently treated immunocompromised patients. Moreover, the data of the hospital pharmacy were analysed to assess the total use of probiotics in the haematology and oncology department.

The Enterol 250 ([Biocodex, France]) was used as a probiotic preparation, containing 250 mg of lyophilised *Saccharomyces boulardii* in each tablet.

Specimens for microbiological cultures were taken from the patients as a standard procedure, according to the following indications: a clinical suspicion of infection (fever > 38 °C or other signs of infection), diarrhoea and when a patient was admitted for a high-toxicity treatment. As a routine procedure, surveillance oral and rectal swabs were taken. The patients who received probiotics were treated according to the same protocol as other patients and did not undergo any additional surveillance.

Mycological cultures of clinical specimens and identification of strains of *Saccharomyces* spp. were done according to the standard laboratory procedures. Clinical samples were inoculated onto Sabouraud agar supplemented with chloramphenicol and gentamycin ([bioMerieux]), and incubated aerobically at 30 °C for 10 days. Identification of the strains of *Saccharomyces* spp. was done using API ID 32 C ([bioMerieux]) tests and matrix-assisted laser desorption-ionisation time of flight mass spectrometry (MALDI-TOF MS) ([MALDI Microflex LT, Bruker, Germany]).

Results

During the study period (January 2011–December 2013), there were 32,000 hospitalisations of haematological patients (including hospitalisations of 116 autologous and 82 allogeneic transplant recipients and daycare unit stays). During this period, the only probiotic administered to the patients in the haematology and oncology department was preparation containing *Saccharomyces boulardii*. The probiotic was given to the patients once daily in the dose of 250 mg of lyophilised *Saccharomyces boulardii*. In total, during the study period,
2270 doses of the preparation were administered to the patients on the ward (Table 1).

During the study, 2816 mycological cultures of the specimens, collected from patients hospitalised in the department of haematology and oncology, were performed. There were 772 positive fungal cultures, comprising 48 rectal swab and 5 oral swab cultures positive for Saccharomyces boulardii, obtained from 38 patients during the study period. There were six blood cultures positive for fungi; however, they comprised Candida species: two C. glabrata, one C. albicans, one C. krusei, one C. tropicalis and one C. parapsilosis. In the studied group of patients, there was no blood culture positive for Saccharomyces spp. To put this data into the perspective, there were 22 blood cultures positive for Saccharomyces boulardii in patients hospitalised in other wards of the hospital—–in internal medicine wards (3 cases), in surgery wards (6 cases) and in the intensive care unit (13 cases).

The basic demographic data of the population of colonised oncohaematological patients are shown in Table 2. The group of colonised patients consisted predominantly of patients with AML, MDS or MM. Colonisation of these patients, detected in the surveillance swabs taken during the whole hospitalisation period, lasted on average for 1–4 weeks, rarely—for up to 3 months. They received the median of three chemotherapy cycles (range 0–16) prior to colonisation, and while colonised, they were hospitalised for 1683 days, with 416 microbiological cultures performed. We have analysed the use of probiotic in 23 of them for the median of 27 days (range 6–69 days) accounting for 1019 doses of the preparation (45% of the probiotics used in the ward during the study period). The probiotics were given due to diarrhoea (10 out of 23) or colonisation with Clostridium difficile with or without diarrhoea (10 out of 23). As mentioned above, we did not identify any invasive infections with Saccharomyces boulardii or with Saccharomyces cerevisiae in this group of patients.

**Discussion**

Probiotics have been used safely for years, and at present, they are indicated for therapy or prophylaxis of many diseases, such as enteral nutrition-related diarrhoea; prevention of C. difficile-associated disease (CDAD) and recurrences of this condition; treatment of irritable bowel syndrome, traveller’s diarrhoea and Crohn’s disease; and reduction of Helicobacter pylori treatment-related symptoms, giardiasis and human immunodeficiency virus-related diarrhoea, as well as to preserve the intestinal bacterial flora during antibiotic therapy [1, 4, 8–16, 26, 33]. Their mechanism of action is not fully understood, but it has been claimed that S. boulardii may directly interact and inhibit C. difficile toxin A [15]. However, their safety—–particularly in immunocompromised patients—–remains a controversial issue [1, 7, 16]. Several authors emphasise that caution is necessary when administering probiotics to the patients with impaired immunity and risk-benefit potential should be evaluated [2, 5, 6, 10, 12, 32]. This is particularly important while administering probiotics containing yeasts to the immunocompromised patients [34]. Damage to the mucusal barriers (e.g. mucositis and oral ulcers often seen in oncohaematological patients) as well as immunosuppression due to the underlying condition or administered treatment (apart from other risk factors) may contribute to invasive fungal infections in this group of patients.

To our knowledge, this is the first report of a wide usage of probiotics in oncohaematological patients. Interestingly, although the use of this probiotic led in some patients to colonisation of the digestive tract with this yeast, there was no single case of sepsis caused by this microorganism in this high-risk population.

We have identified patients colonised with S. boulardii and analysed their probiotic use, which accounts for about half of the use of probiotics in the ward. As this population was treated with chemotherapy courses and had neutropaenia for prolonged periods of time, it seems that S. boulardii has only a limited ability to cause sepsis in this patient population despite severity of their clinical condition. The main indication for Saccharomyces boulardii use was diarrhoea or colonisation with Clostridium difficile. However, with the study design, we did not assess the effectiveness of the probiotic preparation for this indication.

Despite the fact that oncohaematological patients in the studied population were intensively treated with antibiotics (97%) and antifungals (90%) during the period of colonisation with Saccharomyces boulardii, we did not notice any effect of

| Table 1 Use of the probiotics containing Saccharomyces boulardii, occurrence of colonisation with this microorganism and invasive infections in oncohaematological patients |
|---------------------------------------------------------------|
| Number of doses of the probiotic to the patients during the study | Number of patients with colonisation of the digestive tract (detected in oral swabs or stool samples) | Total number of days of observation of colonised patients | Number of mycological cultures performed in the study period in hospitalised oncohaematological patients | Number of invasive infections by Saccharomyces spp. (sepsis or systemic infection) |
|---------------------------------------------------------------|
| 2270 | 38 | 1683 | 2816 | 0 |

The cultures of oral swabs and stool samples were performed for various indications
this treatment on occurrence of invasive infections in this population, although invasive Saccharomyces boulardii infections were recorded in patients hospitalised in other wards of the hospital during the study period. Salonen et al. in a study involving patients with haematological diseases reported isolation of S. cerevisiae from throat, stool, urine, and perineum samples in 16, 23, 10 and 20% of the patients, respectively [35]. Interestingly, in another study, among 70 patients hospitalised for bone marrow transplantation, S. cerevisiae was isolated only once, despite weekly surveillance cultures (primarily of stool and throat swab specimens) during hospitalisation [36]. It is possible that antifungal treatment or prophylaxis—administered as a routine regimen to oncohaematological patients—prevented in our patients progression of S. boulardii colonisation to an invasive infection. In empiric therapy in these patients, voriconazole is used,

### Table 2 General data of the colonised patients included in the study

| Characteristics                                      | Colonised patients (n = 38) and number of hospitalisations (n = 53) |
|------------------------------------------------------|---------------------------------------------------------------|
| Median age on admission in years (range)             | 61 (19–81)                                                   |
| Median hospital stay in days (range)                 | 36 (2–112)                                                   |
| Gender, n (%)                                        |                                                              |
| Female                                               | 20 (53)                                                      |
| Male                                                 | 18 (47)                                                      |
| Disease, n (%)                                       |                                                              |
| Acute myeloid leukaemia                              | 11 (29)                                                      |
| Myelodysplastic syndromes                            | 7 (18)                                                       |
| Multiple myeloma                                     | 7 (18)                                                       |
| Lymphoma                                             | 4 (11)                                                       |
| Chronic myelo-monocytic leukaemia                    | 2 (5)                                                        |
| Acute lymphoblastic leukaemia                        | 2 (5)                                                        |
| Other                                                 | 5 (14)                                                       |
| Cause of hospitalisation, n (%)                      |                                                              |
| Chemotherapy                                         | 26 (68)                                                      |
| Haematopoietic stem cell transplantation              | 5 (14)                                                       |
| Other                                                 | 7 (18)                                                       |
| Probiotic use, n (%)                                  | 26 (72)                                                      |
| Duration of use of probiotic in days (range)         | 27 (6–69)                                                    |
| Indication for Saccharomyces boulardii probiotic, n (%) |                                                              |
| Diarrhoea                                            | 10 (43)                                                      |
| Clostridium difficile (with or without diarrhoea)     | 10 (43)                                                      |
| Unknown                                              | 3 (14)                                                       |
| Median number of microbiological cultures per patient during hospitalisation (range) | 8 (1–41) |
| Median number of mycological stool cultures per patient during hospitalisation (range) | 3 (0–8) |
| Neutropaenia during S. boulardii colonisation, n (%) | 14 (36)                                                      |
| Antibiotic treatment at the time of S. boulardii colonisation, n (%) | 38 (97) |
| Median number of antibiotics used during hospitalisation (range) | 5 (0–10) |
| Antifungal prophylaxis/treatment at the time of S. boulardii colonisation, n (%) | 34 (89) |
| Presence of the central venous catheter, n (%)       | 26 (63)                                                      |
| Parenteral nutrition at any time during hospitalisation, n (%) | 7 (18) |
| Fever during hospitalisation, n (%)                  | 26 (74)                                                      |
| Body mass index (BMI) < 18.5, n (%)                  | 7 (21)                                                       |

As some medical records were not complete, the percentages given in italics are the percentage of data from complete records of this parameter.
which is active against Aspergillus spp., Candida krusei and Candida glabrata, and it may have also prevented invasive infections of S. boulardii/S. cerevisiae aetiology. Indeed, Burkhardt et al. reported a successful treatment of S. boulardii sepsis with voriconazole, while initial treatment with fluconazole was not effective [9].

It appears that S. boulardii/S. cerevisiae may spread on the ward causing an outbreak among hospitalised patients [2, 19, 37]. It should be emphasised that more stringent isolation procedures and other infection control precautions in the haematology/oncology ward diminish the risk of spread of this and other microorganisms among oncohaematological patients. Reports in literature indicate that risk factors predisposing to S. boulardii infections are very similar to those of invasive candidiasis, and clinically, these infections are indistinguishable [1]. It is therefore very important to prevent healthcare-associated infections in these patients, including central venous catheter-related bloodstream infections, as S. boulardii very often causes fungaemia [1, 2, 19, 38–42]. Several authors indicate the need for proper handling of this preparation during its administration [19, 39]. It has been postulated that further studies are needed to evaluate the efficacy of probiotic preparations, to determine the optimal dose and strain of probiotic, and possible adverse events related to their use [7, 14, 32].

This is the first report of an experience with a wide use of probiotics in oncohaematological patients showing no invasive infection or sepsis caused by this microorganism in a large population of patients with impaired immunity. The results of this study justify further studies on the use of probiotics and their safety in oncohaematological patients, as well as evaluation of their efficacy in patients with diarrhoea after chemotherapy, colonised with Clostridium difficile or multi-drug-resistant strains of bacteria, patients with neutropaenia and haematopoietic stem cell transplant recipients.

Compliance with Ethical Standards

Conflict of Interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Enache-Angoulvant A, Hennequin C (2005) Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 41(11):1559–1568. https://doi.org/10.1086/497832
2. Munoz P, Bouza E, Cuenca-Estrella M, Eiros JM, Pérez MJ, Sánchez-Somolinos M, Rincón C, Hortal J, Peláez T (2005) Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 40:1625–1634. https://doi.org/10.1086/429916
3. Herbrecht R, Nivoix Y (2005) Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration. Clin Infect Dis 40:1635–1637. https://doi.org/10.1086/429926
4. Graf C, Gavazzi G (2007) Saccharomyces cerevisiae fungemia in an immunocompromised patient not treated with Saccharomyces boulardii preparation. J Inf Secur 54(3):310–311. https://doi.org/10.1016/j.jinf.2006.01.019
5. Lestin F, Pertschy A, Rimék D (2003) Fungaemia after oral treatment with Saccharomyces boulardii in a patient with multiple comorbidities. Disch Med Wochenschr 128:2531–2533. https://doi.org/10.1055/s-2003-44948
6. Raquelme AJ, Calvo MA, Guzman AM, Depix MS, Garcia P, Perez C, Arrese M, Labarca JA (2003) Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol 36:41–43. https://doi.org/10.1097/00004836-200301000-00013
7. Doron S, Snydman DR (2015) Risk and safety of probiotics. Clin Infect Dis 60:S129–S134. https://doi.org/10.1093/cid/civ085
8. McFarland LV (2010) Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 16(18):2202–2222. https://doi.org/10.3748/wjg.v16.i18.2202
9. Burkhardt O, Kohnelein T, Pletz M, Welte T (2005) Saccharomyces boulardii induced sepsis: successful therapy with voriconazole after treatment failure with fluconazole. Scand J Infect Dis 37:69–72. https://doi.org/10.1080/003655405100026545
10. Thygessen JB, Glenup H, Tarp B (2012) Saccharomyces boulardii fungemia caused by treatment with a probioticum. BMJ Case Rep 2012; doi: https://doi.org/10.1136/bcr.06.2011.4412
11. Lherm T, Monet C, Nougire B, Soulier M, Larbi D, Le Gall C, Caen D, Malbrunot C (2002) Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 28:797–801. https://doi.org/10.1007/s00134-002-1267-9
12. Santino I, Alari A, Bono S, Teti E, Marangi M, Bernardini A, Magrini L, Di Somma S, Teaggi A (2014) Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum. Int J Immunopharmacol Pharmacol 27(1):143–146
13. Fredenucci I, Chomarat M, Boucaud C, Flandrois JP (1998) Saccharomyces boulardii fungemia in a patient receiving Ultralevure therapy. Clin Infect Dis 27(1):222–223
14. Lau CS, Chamberlain RS (2016) Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med 9:27–37. https://doi.org/10.2147/IJGM.S98280
15. Hickson M (2011) Probiotics in the prevention of antibiotic-associated diarrhea and Clostridium difficile infection. Ther Adv Gastroenterol 4:185–197. https://doi.org/10.1177/1756283X11399115
16. Boyle RJ, Robins-Browne RM, Tang MLK (2006) Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 83(6):1256–1264
17. Cohen L, Ranque S, Raoul D (2013) Saccharomyces cerevisiae boulardii transient fungemia after intravenous self-inoculation. Med Mycol Case Rep 3:223–224. https://doi.org/10.1016/j.mycpcm.2013.02.003
18. Lolis N, Veldekis D, Moraitou H, Kanavaki S, Velegraki A, Triandafyllidis C, Tasiousis C, Pefanis A, Pneumatikos I (2008) Saccharomyces cerevisiae fungemia in an intensive care unit patient treated with caspofungin. Curr Care 12:414. https://doi.org/10.1186/cc8643
19. Cassone M, Serra P, Mondello F, Girolamo S, Scafetti S, Pistella E, Venditti M (2003) Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighbouring those treated with a...
probiotic preparation of the organism. J Clin Microbiol 41(11):5340–5343. https://doi.org/10.1128/JCM.41.11.5340-5343.2003

20. Alves da Silva FH, Ribeiro Paço F, Reis E, Amaral V (2011) *Saccharomyces cerevisiae* infection— an unusual pathogen in the ICU. Rev Bras Ter Intensiva 23(1):108–111. https://doi.org/10.1590/S0103-507X2011000100017

21. Atacca S, Soysala A, Karadeniz Cerib K, Yılmaz S, Aksue B, Kiyabın G, Bakır M (2017) Catheter-related *Saccharomyces cerevisiae* fungemia following *Saccharomyces boulardii* probiotic treatment: in a child in intensive care unit and review of the literature. Med Mycol Case Rep 15:33–35. https://doi.org/10.1016/j.mycasrep.2017.02.002

22. Rijnders B, Van Wijngaerden E, Vervaest C, Peetmans WE (2000) *Saccharomyces* fungemia complicating *Saccharomyces boulardii* treatment in a non-immunocompromised host. Intensive Care Med 26(6):825. https://doi.org/10.1007/s001340051261

23. Seng P, Cerlier A, Cassagne C, Coulange M, Legre R, Stein A (2016) *Saccharomyces cerevisiae* osteomyelitis in an immunocompetent baker. IDCases 5:1–3. https://doi.org/10.1016/j.idcr.2016.05.002

24. Martin IW, Tonner R, Trivedi J et al (2017) *Saccharomyces boulardii* probiotic-associated fungemia: questioning the safety of these preventive probiotic’s use. Diagn Microbiol Infect Dis 87:286–288. https://doi.org/10.1016/j.diagmicrobio.2016.12.004

25. Schalk E, Bohr UR, König B, Mohren M (2010) *Clostridium difficile*-associated diarrhoea, a frequent complication in patients with acute myeloid leukaemia. Ann Hematol 89(1):9–14. https://doi.org/10.1007/s00277-009-0772-0

26. Dinleveci EC, Kara A, Ozen M, Vandenplas Y (2014) *Saccharomyces boulardii* CNCM I-745 in different clinical conditions. Expert Opin Biol Ther 14(11):1593–1609. https://doi.org/10.1517/14712598.2014.937419

27. Videlock EJ, Cremonini F (2012) *Clostridium difficile*-associated diarrhoea. Aliment Pharmacol Ther 35(12):1355–1369. https://doi.org/10.1111/j.1365-2036.2012.05104.x

28. Cesaro S, Cinello P, Rossi L, Zanesco L (2000) *Saccharomyces cerevisiae* fungemia in a neutropenic patient treated with *Saccharomyces boulardii*. Support Care Cancer 8(6):504–505

29. Tomblyn M, Chiller T, Emserle H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ (2009) Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 15(10):1143–1238. https://doi.org/10.1016/j.bbmt.2009.06.019

30. Antony SJ, Stratton CW, Dummer JS (1996) *Lactobacillus* bacteremia: description of the clinical course in adult patients without endocarditis. Clin Infect Dis 23:773–778

31. Oliver MR, Van Voorhis WC, Boeckh M, Mattson D, Bowden RA (1996) Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine. Clin Infect Dis 22:521–524

32. Hempel S, Newberry S, Ruelaz A, Wang Z, Miles JN, Suttrop MJ, Johnsen B, Shanman R, Slusser W, Fu N, Smith A, Roth B, Polak J, Motala A, Perry T, Shekelle PG (2011) Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess 200:1–645

33. Kelesidis T, Pothoulakis C (2012) Efficacy and safety of the probiotic *Saccharomyces boulardii* for the prevention and therapy of gastrointestinal disorders. Therap Adv Gastroenterol 5(2):111–125. https://doi.org/10.1717/1756283X11428502

34. Enache-Angoulvant A, Hennequin C (2005) Invasive *Saccharomyces* infection: a comprehensive review. Clin Infect Dis 41(11):1559–1568

35. Salonen JH, Richardson MD, Gallacher J, Helenius H, Lehtonen OP, Nikoskelainen J (2000) Fungal colonization of haematological patients receiving cytoxic chemotherapy: emergence of azole-resistant *Saccharomyces cerevisiae*. J Hosp Infect 45:293–301. https://doi.org/10.1053/jhin.1999.0718

36. Zerva L, Hollis RJ, Pfalner MA (1996) *In vitro* susceptibility testing and DNA typing of *Saccharomyces cerevisiae* clinical isolates. J Clin Microbiol 34:3031–3034

37. Olver WJ, James SA, Lennard A, Galloway A, Roberts IN, Boswell TC, Russell NH (2002) Nosocomial transmission of *Saccharomyces cerevisiae* in bone marrow transplant patients. J Hosp Infect 52:268–272. https://doi.org/10.1053/jhin.2002.1314

38. Hennequin C, Kauffmann-Lacroix C, Jobert A, Viard JP, Ricour C, Jacquemin JL (2000) Possible role of catheters in *Saccharomyces boulardii* fungemia. Eur J Clin Microbiol Infect Dis 19:16–20. https://doi.org/10.1007/s100960050003

39. Venugopalan V, Shriner KA, Wong-Beringer A (2010) Regulatory oversight and safety of probiotic use. Emerg Inf Dis 16(11):1661–1665. https://doi.org/10.3201/eid1611.100574

40. Trautmann M, Synowzik I, Nadji-Ohl M, Con Voigt T, Reiter W (2008) Fungemia due to *Saccharomyces cerevisiae* var. *boulardii*. Chemother J 17:57–61

41. Niault M, Thomas F, Prost J, Ansari FH, Kalfon P (1999) Fungemia due to *Saccharomyces* species in a patient treated with enteral *Saccharomyces boulardii*. Clin Infect Dis 28:930. https://doi.org/10.1086/517255

42. Bassetti S, Frei R, Zimmerli W (1998) Fungemia with *Saccharomyces cerevisiae* after treatment with *Saccharomyces boulardii*. Am J Med 105(1):71–72. https://doi.org/10.1016/S0002-9343(98)00133-8